CJC-1295 (without DAC)
Research Overview · Mechanism of Action · Reconstitution Guide
Overview
CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF 1-29) is a 29-amino acid synthetic analogue of growth hormone-releasing hormone (GHRH). Four amino acid substitutions (Ala2→D-Ala, Gln8→Ala, Ala15→Ala, Leu27→Ala) protect against enzymatic degradation by DPP-IV and other proteases, extending its half-life to approximately 30 minutes compared to native GHRH's 2–7 minutes. Without the drug affinity complex (DAC), it produces a more physiological, pulsatile GH release pattern.
Mechanism of Action
CJC-1295 (no DAC) binds GHRH receptors on anterior pituitary somatotrophs, activating adenylyl cyclase via Gs coupling and elevating intracellular cAMP. This stimulates GH synthesis and pulsatile secretion. The short half-life preserves the natural pulsatile pattern of GH release, which is important for maintaining receptor sensitivity and downstream IGF-1 signaling. When co-administered with a GHSR agonist (e.g., ipamorelin), synergistic GH release is observed through dual receptor pathway activation.
Key Studies & References
Jetté L et al. (2005). hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: a comparison of the pharmacokinetics. Endocrinology 146:3052–3058.
Ionescu M & Frohman LA (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab 91:4792–4797.
Bacteriostatic Water Reconstitution Guide
Research Use Only — The following reconstitution information is provided for in vitro laboratory research purposes only. Not for human or veterinary use.
Recommended Solvent
Bacteriostatic water (0.9% benzyl alcohol)
Standard Volume
Add 2 mL bacteriostatic water to a 2 mg vial to yield a 1000 mcg/mL solution.
Working Concentration
1000 mcg/mL standard working concentration.
Storage (Reconstituted)
Reconstituted: 2–8°C, use within 28 days. Lyophilized: -20°C, desiccated.
Stability Window
28 days refrigerated. Stable in bacteriostatic water.
Technique
Inject solvent slowly down the vial wall. Swirl gently. Dissolves readily within 60 seconds.
Notes
CJC-1295 no DAC has a short in vivo half-life (~30 min) but is stable in solution. Research protocols typically administer shortly before or after GHSR agonists to maximize synergistic GH pulse.
Research Dosing Reference
The following dosing information is derived from published preclinical research literature and is provided for reference purposes only.
Clinical / Human Research Range
Research protocols: 100–200 mcg subcutaneous, typically co-administered with a GHS.
Preclinical Models
Rodent studies: 100–300 mcg/kg subcutaneous.
Calculation Example
For a 1000 mcg/mL solution: a 100 mcg dose = 0.1 mL (10 units on a 100-unit insulin syringe).